secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeStance Health Group, Inc. (LFST)
CIK:        0001845257
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023246
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeStance Q3 rev +25% to $217.6M; cuts FY22 guidance on lower visits, higher health costs; CEO/CFO changes
--------------------------------------------------------------------------------

- Q3 revenue $217.6M (+25% YoY); net loss $37.9M vs $120.5M loss; Adjusted EBITDA $15.4M (+44%).
- Full-year 2022 guidance lowered: revenue $845-850M, Center Margin $229-232M, Adjusted EBITDA $50-53M.
- Ken Burdick appointed Chairman & CEO effective Sept 7, succeeding Michael Lester (remains strategic advisor).
- CFO transition: J. Michael Bruff to Business Transformation Officer; David Bourdon to become CFO Nov 10.
- Ended Q3 with $90.3M cash, $212.0M net debt; total clinicians 5,431 (+24% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/0000950170-22-023246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/lfst-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer